Retatrutide in Jacksonville: Is It Available, and How Does It Compare With Tirzepatide?

Woman preparing a once-weekly weight loss injection pen at home, the delivery format retatrutide uses

Retatrutide in Jacksonville: Is It Available, and How Does It Compare With Tirzepatide?

Medically reviewed by Elyssa Blissenbach, MD · Board Certified, American Boards of Internal Medicine & Obesity Medicine

Licensed to practice in FL, GA, SC, AL, VA, NC · NPI #1881601714 · Last reviewed: 2026-10-28

Key Takeaways

  • Retatrutide is not FDA approved and cannot legally be prescribed or sold anywhere in the U.S. — including Jacksonville. Eli Lilly plans to file with the FDA in early 2027.
  • In its pivotal Phase 3 trial it produced the largest average weight loss ever recorded for an obesity medication: 28.3% of body weight at 80 weeks.
  • Tirzepatide (Zepbound, Mounjaro) remains the strongest FDA-approved option — about 21% average loss — and is available in Jacksonville today.
  • Anything sold online as “retatrutide” right now is an unregulated research chemical, not a medication.

Retatrutide is the drug behind most of this year’s weight loss headlines, and the headlines are not hype: in Phase 3 trials reported in 2026, people lost more weight on it than on any obesity medication ever tested. Naturally, patients are already asking us whether they can get it in Jacksonville.

The short answer: not yet, and not from anyone — and the “from anyone” part matters, because an unregulated gray market has sprung up to fill the gap. Here is where retatrutide actually stands, what the trial numbers show, and how it stacks up against tirzepatide, the strongest medication you can legitimately start today.

What Is Retatrutide?

Retatrutide is an investigational once-weekly injection from Eli Lilly — the same company that makes tirzepatide (Mounjaro, Zepbound). Where semaglutide activates one gut-hormone receptor (GLP-1) and tirzepatide activates two (GLP-1 and GIP), retatrutide activates three: GLP-1, GIP, and glucagon. That has earned it the nickname “triple agonist” or “triple G.”

The first two receptors work the way patients on current GLP-1 medications already know: slower stomach emptying, quieter food noise, earlier fullness. The third — glucagon — is the new ingredient. Activating it appears to increase the calories your body burns and reduce fat stored in the liver, so retatrutide works on the energy-out side of the equation, not just appetite.

What Did the Phase 3 Trials Show?

Lilly’s Phase 3 program is called TRIUMPH, and 2026 has been its year — four trials have now reported results:

Trial Reported Population Average Weight Loss (highest dose)
TRIUMPH-4 December 2025 Obesity with knee osteoarthritis 28.7%
TRIUMPH-1 May 2026 Obesity (pivotal trial, 2,339 adults) 28.3% at 80 weeks
TRIUMPH-2 July 2026 Obesity with type 2 diabetes 20.8%, with A1C reduced up to 1.6 points
TRIUMPH-3 July 2026 Severe obesity with cardiovascular disease 22.6% (55.8 lbs)

Two details from TRIUMPH-1 stand out. In a pre-specified extension, participants who stayed on the highest dose for a full two years averaged 30.3% body weight loss — and 45% of people on the top dose lost 30% or more. Average results in that range were previously the territory of bariatric surgery, not a weekly injection.

The trade-off showed up in the same data: side effects were the familiar GI profile of this medication class (nausea affected up to 28% of people at the top dose), plus a skin-tingling sensation called dysesthesia reported by roughly one in eight. About 11% of participants on the highest dose stopped because of side effects — higher than the roughly 6% seen with tirzepatide in its own pivotal trial.

Is Retatrutide Available in Jacksonville?

No. Retatrutide is not FDA approved for any condition, which means no pharmacy, weight loss clinic, med spa, or telehealth company in Jacksonville — or anywhere else in the United States — can legally prescribe or dispense it. That is not a Jacksonville limitation; it is the drug’s regulatory status.

The realistic timeline: Lilly has said it plans to submit retatrutide to the FDA in early 2027. FDA review of a new obesity drug typically takes six months to a year after filing, which puts the earliest plausible pharmacy availability in late 2027 or 2028. Until then, the only legitimate way anyone receives retatrutide is inside a registered clinical trial — and the major TRIUMPH obesity trials have already finished enrolling.

A Warning About “Retatrutide” Sold Online

Search for retatrutide and you will find websites selling vials of it today, usually labeled “for research purposes only.” Those products are not a loophole — they are the problem the label warns you about. Because retatrutide is unapproved, it cannot legally be compounded for human use the way semaglutide and tirzepatide briefly could during their shortages, and no regulator inspects what goes into those vials. Purity, dose accuracy, and sterility are unknowns you inject at your own risk, and the FDA has repeatedly warned about counterfeit and research-grade weight loss peptides.

A simple rule keeps you safe: if someone will sell you retatrutide before the FDA has approved it, that is the reason not to buy from them.

How Does Retatrutide Compare With Tirzepatide?

Tirzepatide (Zepbound/Mounjaro) Retatrutide
Status FDA approved, available now Investigational; FDA filing planned early 2027
Receptors GLP-1 + GIP (dual) GLP-1 + GIP + glucagon (triple)
Average weight loss ~21% at 72 weeks (SURMOUNT-1) 28.3% at 80 weeks (TRIUMPH-1)
Stopped due to side effects ~6% at highest dose ~11% at highest dose
Dosing Weekly injection Weekly injection

Two honest caveats belong next to that table. First, these are different trials with different participants, so the comparison is approximate — the first true head-to-head study (TRIUMPH-5, retatrutide vs. tirzepatide directly) finished recruiting and is expected to read out in 2027. Second, averages hide range: plenty of tirzepatide patients lose well beyond 21%, and the practical difference for any individual patient is smaller than the headline gap suggests.

The fair summary: retatrutide looks like more power with more side effects, and tirzepatide is the proven option you do not have to wait for. For how tirzepatide compares with semaglutide — the decision patients actually face today — see our semaglutide vs. tirzepatide guide.

What Should Jacksonville Patients Do Right Now?

If extra weight is affecting your health today, waiting one to two years for an unapproved drug is a strategy with a real cost — especially when the available option averages results that were considered surgical-territory five years ago. Starting now and switching later is routine medicine: patients already move between semaglutide and tirzepatide as their needs change, and retatrutide, if approved, will slot into the same decision the same way.

Both current medication families are available at Get Skinny Jax — tirzepatide programs and semaglutide programs — and whether you’re a good candidate gets sorted out at a free consultation with a board-certified obesity medicine physician. When retatrutide is approved, our patients will hear it from us — not from a headline.

Frequently Asked Questions

Is retatrutide FDA approved?

No. As of late 2026, retatrutide is an investigational drug. Its Phase 3 trials have reported strong results, and Eli Lilly plans to submit it to the FDA in early 2027, but it is not approved for any use today.

Can I get retatrutide in Jacksonville?

No clinic, pharmacy, or telehealth provider in Jacksonville can legally prescribe or dispense retatrutide, because it is not FDA approved. Anyone selling it today is selling an unregulated research chemical with no verified purity, dose, or sterility.

How much weight do people lose on retatrutide?

In the pivotal TRIUMPH-1 trial, people on the highest dose lost an average of 28.3% of their body weight at 80 weeks, and 30.3% among those who continued to two years. Forty-five percent of top-dose participants lost 30% or more.

Is retatrutide better than tirzepatide?

Its trial averages are higher — roughly 28% versus 21% — but those come from separate trials, and retatrutide also showed more side effects, with about 11% of participants stopping versus about 6% on tirzepatide. The first direct head-to-head trial (TRIUMPH-5) is expected to report in 2027.

When will retatrutide be available?

Eli Lilly plans to file with the FDA in early 2027. If the review goes smoothly, the earliest realistic pharmacy availability is late 2027 to 2028.

Should I wait for retatrutide or start treatment now?

For most patients, starting an FDA-approved medication now makes more medical sense than waiting a year or more — the health effects of excess weight do not pause, tirzepatide’s results are strong in their own right, and switching medications later is routine. A consultation can sort out which current option fits your history and goals.


This article is informational and not a substitute for medical advice. Retatrutide is an investigational drug and is not available by prescription. Talk to a licensed provider before starting any prescription medication.